Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05788536 · ClinicalTrials.gov registry record · Phase 1
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
A Phase 1 study of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 15
- Study locations
NCT05788536 is a Phase 1 study of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 30 participants. The trial reports 15 study locations across 9 states.
The verdict
NCT05788536, a Phase 1 study of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 15
- Study locations
Study Summary
Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) * Evaluate the efficacy of DB-OTO (how well DB-OTO works)
Conditions Studied
Interventions
- GENETIC DB-OTO
Study Locations (15)
Other
- University Hospital Tubingen - Tübingen
- Hospital Universitario Materno Infantil en las Palmas de Gran Canaria - Las Palmas de Gran Canaria
- Ramon y Cajal University Hospital - Madrid
- Addenbrooke's Hospital, Cambridge University Hospitals NHS FT - Cambridge
- Great Ormond Street Hospital For Children NHS Foundation Trust - London
California
- University of California Los Angeles Medical Center - Los Angeles
- Rady Children's Hospital - San Diego
Florida
- Nemours Children s Clinic - Jacksonville
- Nemours Childrens Hospital - Orlando
Massachusetts
- Boston Children's Hospital - Main - Boston
New York
- Columbia University Irving Medical Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Washington
- Seattle Children's Hospital - Seattle
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2031-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05788536
The ClinicalTrials.gov registry entry for NCT05788536 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) appearing as the primary indexed condition, and to 1 intervention - of which DB-OTO is the first listed.
NCT05788536 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05788536 about?
NCT05788536 is a clinical study titled "A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations". Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the safety of DB-OTO * Determine how well DB-O...
What is the current status of trial NCT05788536?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-27. Estimated completion is 2031-04-19.
What conditions does trial NCT05788536 study?
This clinical trial studies the following conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF).
What interventions are being tested in trial NCT05788536?
The interventions under investigation include: DB-OTO (GENETIC).
Who is sponsoring clinical trial NCT05788536?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05788536 being conducted?
This trial has 15 study locations across California, Florida, Massachusetts, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.